Generic Medicine Info
Indications and Dosage
Disorders associated with reduced gastrointestinal motility, Gastro-oesophageal reflux disease, Non-ulcer dyspepsia
Adult: 5-10 mg 3-4 times daily. Max: 40 mg/day.
Renal Impairment
Reduce initial dose in patients with renal impairment.
Hepatic Impairment
Reduce dose to ½ in patients with hepatic impairment.
Should be taken on an empty stomach. Take 15 min before meals. Avoid grapefruit juice.
Hypersensitivity. GI haemorrhage, obstruction or perforation; patients on oral or parenteral azole antifungals; erythromycin, clarithromycin and troleandomycin. Premature neonates with gestational age ≤3 mth. History of irregular heart beat, abnormal ECG, heart disease, pulmonary disease, dehydration or persistent vomiting. Pregnancy.
Special Precautions
Elderly; renal or hepatic impairment. Patients in whom increase in GI motility could be harmful. Lactation.
Adverse Reactions
Abdominal cramps, borborygmi and loose stools (transient); rarely require discontinuation of therapy. Headache and lightheadedness (rare). Hypersensitivity, convulsions, frequent urination.
Drug Interactions
Sedative effects of benzodiazepines and alcohol may be enhanced. Prothrombin time in patients on anticoagulants may be increased. Effect antagonised by anticholinergic drugs. Avoid cisapride with antiallergics, antibacterials, antidepressants, antifungals, antinauseants, antipsychotics and protease-inhibitors. Cisapride increases the GI absorption of cimetidine and ranitidine. Grapefruit juice increases bioavailability of cisapride, avoid concomitant use.
Food Interaction
Food increases the bioavailability.
Mechanism of Action: Cisapride increases GI motility by enhancing the release of acetylcholine at the myenteric plexuses in the gut plain muscle. It increases lower oesophageal sphincter pressure, shortens gastric transit time, reduces oesophageal reflux and facilitates healing of oesophageal ulcers. It also increases small intestine activity.
Onset: 30-60 minutes.
Duration: 7-10 hr.
Absorption: Readily absorbed in the GI tract; peak plasma concentrations after 1-2 hr (oral).
Distribution: Enters breast milk (small amounts); protein-binding: 98%.
Metabolism: Extensively hepatic; converted to norcisapride.
Excretion: Urine and faeces (as metabolites); 10 hr (elimination half-life).
Store below 25°C.
MIMS Class
GIT Regulators, Antiflatulents & Anti-Inflammatories
Disclaimer: This information is independently developed by MIMS based on Cisapride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in